The evidence leans constructive4 supporting, 1 against, 0 worth knowing
Supporting
trading 26% above its 200-day average
up 4% over twelve months
3 independent kinds of evidence agree today, which is uncommon
revenue grew 42% year on year in the quarter ending 2026-06-30
Against
net margin has narrowed from 10.9% to 6.6% across four quarters
Worth knowing
nothing the data supports either way
What would change this read: a close below 417, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
How it has performed
price return over each window, measured against zero
What the scans say today
9 of 47 matched on 2026-08-21
UNICHEMLAB matches 9 of the 47 scans today, across 3 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
Return on capital uses profit before tax over equity plus borrowings. The textbook version adds finance costs back; those are not tagged reliably in quarterly filings, so this understates the ratio for a heavily borrowed company rather than flattering it. Balance sheets are filed half-yearly, so these can be up to six months behind the profit figures above.
Valuation against its own history
477 sessions since 2024-09-06
6×
median 238×
355×
now 10×
UNICHEMLAB trades at 10× trailing earnings, below its median of 238× over this window — 96% less expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
AGM / EGM filings were typically +0.00pt vs the market over the next 5 sessions (n=4,362) · Results filings were typically -0.52pt vs the market over the next 5 sessions (n=7,520) · Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 42% against the same quarter a year earlier
profit rose 348% year on year
net margin widened from 1.9% to 6.6%
revenue rose in 3 of the last 4 quarters
Going against it
nothing clear in the filed numbers
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · consolidated
633
49
41
6.61
6.6%
Q4 FY26
2026-03-31 · consolidated
575
19
11
1.55
1.9%
Q3 FY26
2025-12-31 · consolidated
521
293
264
37.54
50.7%
Q3 FY25
2024-12-31 · consolidated
533
62
58
8.22
10.9%
Q2 FY25
2024-09-30 · consolidated
462
33
30
4.34
6.6%
Q1 FY25
2024-06-30 · consolidated
446
15
9
1.31
2.1%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+2.1%
Versus 200-day average+26.2%
Below 52-week high-19.1%
Above 52-week low+85.2%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)55.8
Higher closes in last 53 of 5
Six-month return+50.18%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.